2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Sodium Channel

Sodium Channel

Na channels; Na+ channels

Sodium Channel

Related Products

PDF 3.33 MB

Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential.

Sodium Channel Isoform Specific Products:

Sodium Channel Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-13295S
    Vinpocetine-d5
    		Inhibitor
    Vinpocetine-d5 is the deuterium labeled Vinpocetine. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders.
    Vinpocetine-d<sub>5</sub>
  • HY-A0078R
    Mebeverine hydrochloride (Standard)
    		Inhibitor
    Mebeverine (hydrochloride) (Standard) is the analytical standard of Mebeverine (hydrochloride). This product is intended for research and analytical applications. Mebeverine hydrochloride, a β-phenylethylamine derivative, is a musculotropic agent that potently blocks intestinal peristalsis. Mebeverine directly blocks voltage-operated sodium channels and inhibits intracellular calcium accumulation.
    Mebeverine hydrochloride (Standard)
  • HY-167852
    GX-585
    		Inhibitor
    GX-585 is a sulfonamide analog that acts as a Nav1.7 channel inhibitor, demonstrating analgesic activity in treating neuropathic pain and inflammation.
    GX-585
  • HY-139786A
    Cofirasersen sodium
    		Inhibitor
    Cofirasersen sodium is designed to reduce the expression of ENaC in the lung. ENaC is a sodium transport channel and believed to be hyperactive in cystic fibrosis, which is caused by mutations in the cystic fibrosis transmembrane regulator gene.
    Cofirasersen sodium
  • HY-W415121
    Bupivacaine hydrochloride monohydrate
    		Inhibitor
    Bupivacaine hydrochloride monohydrate is a NMDA receptor inhibitor. Bupivacaine hydrochloride monohydrate can block sodium, L-calcium, and potassium channels. Bupivacaine hydrochloride monohydrate potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine hydrochloride monohydrate can be used for the research of chronic pain.
    Bupivacaine hydrochloride monohydrate
  • HY-B0480AR
    Brompheniramine (Standard)
    		Inhibitor
    Brompheniramine (Standard) is the analytical standard of Brompheniramine. This product is intended for research and analytical applications. Brompheniramine ((±)-Brompheniramine) is a potent and orally active antihistamine of the alkylamine class. Brompheniramine is a selective histamine H1 receptor antagonist with a Kd of 6.06 nM. Brompheniramine can block the hERG channels, calcium channels, and sodium channels with IC50s of 0.90 μM, 16.12 μM and 21.26 μM, respectively. Brompheniramine has anticholinergic, antidepressant and anesthetic properties and can be used for allergic rhinitis research[4].
    Brompheniramine (Standard)
  • HY-49066
    Sodium Channel inhibitor 4
    		Inhibitor 98.0%
    Sodium Channel inhibitor 4 is a sodium channel inhibitor.
    Sodium Channel inhibitor 4
  • HY-181615
    Nav1.8-IN-22
    		Inhibitor
    Nav1.8-IN-22 (Formula I) is a Nav1.8 sodium channel inhibitor. Nav1.8-IN-22 regulates sodium channel activity by directly binding to Nav1.8. Nav1.8-IN-22 is applicable for pain-related research.
    Nav1.8-IN-22
  • HY-W744263
    Eslicarbazepine Acetate-d3
    Eslicarbazepine Acetate-d3 is the deuterium labeled Eslicarbazepine acetate (HY-B0703). Eslicarbazepine acetate (BIA 2-093), an antiepileptic agent, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel.
    Eslicarbazepine Acetate-d<sub>3</sub>
  • HY-P5153
    ProTx-III
    		Inhibitor
    ProTx-III is a selective and potent inhibitor of voltage-gated sodium channel Nav1.7, with an IC50 of 2.1 nM. ProTx-III is a spider venom peptide isolated from the venom of the Peruvian green velvet tarantella. ProTx-III has a typical inhibitor cystine knot motif (ICK). ProTx-III is able to reverse the pain response. ProTx-III can be used to study diseases such as chronic pain, epilepsy, and arrhythmia.
    ProTx-III
  • HY-180847
    Quinisocaine
    Quinisocaine is a topical anesthetic used for the study of pain and pruritus.
    Quinisocaine
  • HY-125667
    PA1
    		Inhibitor
    PA1 is a photoswitchable epithelial sodium channel (ENaC) blocker. PA1 can switch to cis-PA1 at 400nm and trans-PA1 at 500nm. PA1 inhibits δ/αENaC, αβγENaC, and δβγENaC, with IC50 values of 4.3nM, 90 nM, and 390 nM, respectively.
    PA1
  • HY-16738
    Eleclazine
    		Inhibitor 98.0%
    Eleclazine (GS 6615) is a selective cardiac late sodium current inhibitor and a weak inhibitor of potassium current with IC50 of <1 μM and approximately 14.2 μM, respectively. Eleclazine shows concurrent protection against autonomically induced atrial premature beats, repolarization alternans and heterogeneity, and atrial fibrillation in porcine model. Eleclazine can be used to research cardiac arrhythmias.
    Eleclazine
  • HY-12155
    JNJ-26990990
    		Inhibitor
    JNJ-26990990 is a broad-spectrum antiepileptic agent with oral activity. JNJ-26990990 can inhibit voltage-gated Na+ channels and N-type Ca2+ channels, but has a very weak inhibitory effect on human carbonic anhydrase-II (IC50 = 110 μM).
    JNJ-26990990
  • HY-164684
    Dichlorobenzamil
    		Inhibitor
    Dichlorobenzamil (3',4'-Dichlorobenzamil; L-594881) is an effective Na/Ca exchange inhibitor. Dichlorobenzamil significantly inhibits 45Ca uptake mediated by reverse Na/Ca exchange in pancreatic islet cells (IC50 = 18 μM). Dichlorobenzamil can also block K+ channels and voltage-sensitive Ca2+ channels.
    Dichlorobenzamil
  • HY-105059A
    Denzimol hydrochloride
    		Inhibitor
    Denzimol hydrochloride is an orally active anticonvulsant agent. Denzimol hydrochloride inhibits cytochrome P450, and interacts with benzodiazepine receptors. Denzimol hydrochloride selectively antagonizes tonic components of Metrazol-induced seizures in rats and mice. Denzimol hydrochloride can be used for the research of epilepsy and convulsions.
    Denzimol hydrochloride
  • HY-141547
    Nav1.7-IN-8
    		Inhibitor
    Nav1.7-IN-8 is a potent blockage of NaV1.7 with high selectivity for the inhibition of NaV1.7 over the subtypes hNaV1.1 and hNaV1.5. Nav1.7-IN-8 inhibits CYP2C9 and CYP3A4 with an IC50 of 0.17 μM and 0.077 μM, respectively. Nav1.7-IN-8 displays significant analgesic effects in rodent models of acute and inflammatory pain.
    Nav1.7-IN-8
  • HY-128794
    PF-05150122
    PF-05150122 is a novel potent and selective human Nav1.7 channel blocker with the activity of inhibiting human pain signaling. PF-05150122 exhibited favorable biopharmacokinetic parameters in microdose studies, providing a basis for exploring its application in acute or chronic pain inhibition. The pharmacokinetic model of PF-05150122 predicted that at the corresponding oral dose, it could effectively reduce the 50% inhibitory concentration (IC50) of Nav1.7, demonstrating its inhibitory potential.
    PF-05150122
  • HY-106731
    KT 2-230
    		Inhibitor
    KT 2-230 is a sodium channel and calcium channel blocker with anti-inflammation effects.
    KT 2-230
  • HY-142957
    NaPi2b-IN-1
    		Inhibitor
    NaPi2b-IN-1 is a potent and orally active inhibitor of sodium-dependent phosphate transport protein 2b (NaPi2b) with an IC50 of 64 nM. NaPi2b is primarily expressed in the small intestine, lungs, and testes and plays an important role in phosphate homeostasis. NaPi2b-IN-1 has the potential for the research of hyperphosphatemia.
    NaPi2b-IN-1
Cat. No. Product Name / Synonyms Application Reactivity
Sodium Channel Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.